News

Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the company’s new oral obesity drug Foundayo, but shares recovered as analysts argued the reaction may have been overdone. The episode shifted investor attention toward the ...

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% a

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

The drugmaker's total Indiana capital commitments since 2020 now exceed $21 billion, with a new genetic medicine facility opening in Lebanon

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti

Moby summary of Alkermes plc's Q1 2026 earnings call

Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Competition from Eli Lilly puts pressure on margins despite strong early uptake

Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.

Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

Eli Lilly (NYSE:LLY) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back sharply from their February peak. That gap between operating performance and stock price is where our model sees opportunity. Our 24/7 Wall St. price target for Eli Lilly is $1,133.12 over the next 12 months, ... Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months

Eli Lilly is coming off an impressive first-quarter performance, with sales soaring by 56%.

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H

ABBV jumps 5% after a Q1 beat and higher 2026 guidance, but Skyrizi, Rinvoq and a deep pipeline may matter more for its post-earnings outlook

Liver failure report raises early questions post launch

We recently published Jim Cramer Commented On Big Market Confusion & Discussed These 20 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer. Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s favorite stocks in the space. The shares are up by 16.9% over the past year […]

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut

Eli Lilly stock toppled Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

I keep buying Eli Lilly (NYSE:LLY), and the latest quarter just made it harder to stop. This is a confession of conviction. I have been adding through every dip in 2026, and the most recent earnings report told me the thesis is accelerating. What pulls me back to the buy button is simple. Lilly sits ... This Pharma Stock Keeps Earning My Money, Here’s Why